AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20688454 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home print materials (for print and half of video participants)
Number of subjects: 0
Study 20688454 — intervention group
Group type: COMPARATOR
Intervention: No education (control group)
Number of subjects: 0
Study 18721120 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual hyperinflation with positive end expiratory pressure followed by suction
Number of subjects: 55
Study 18721120 — intervention group
Group type: COMPARATOR
Intervention: Suction only
Number of subjects: 55
Study 16422908 — intervention group
Group type: EXPERIMENTAL
Intervention: Labial photoplethysmograph (LP)
Number of subjects: 15
Study 16422908 — intervention group
Group type: COMPARATOR
Intervention: Vaginal photoplethysmograph (VP)
Number of subjects: 15
Study 12865509 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine group II (0.5% lignocaine infiltration at each pin site)
Number of subjects: 30
Study 12865509 — intervention group
Group type: COMPARATOR
Intervention: Control group I (pins applied without any scalp infiltration)
Number of subjects: 30
Study 12865509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during pinning
Number of subjects: 30
Study 10232413 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum in patients with OA at work
Number of subjects: 16
Study 10232413 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil cationic protein (ECP) in induced sputum in patients with OA at work
Number of subjects: 16
Study 10232413 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophil count in patients with OA at work
Number of subjects: 16
Study 10232413 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ECP levels in patients with OA at work
Number of subjects: 16
Study 8912740 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV alone (15, 20, and 25 cm H2O)
Number of subjects: 8
Study 8912740 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV combined with PEEP of 5 cm H2O (reducing PSV to 10, 15, and 20 cm H2O)
Number of subjects: 8
Study 8912740 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing (SB)
Number of subjects: 8
Study 1666933 — intervention group
Group type: EXPERIMENTAL
Intervention: RIBA‐2
Number of subjects: 732
Study 1666933 — intervention group
Group type: COMPARATOR
Intervention: RIBA‐1
Number of subjects: 732
Study 6132613 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg kg‐1
Number of subjects: 0
Study 6132613 — intervention group
Group type: COMPARATOR
Intervention: Diazemuls 0.15 mg kg‐1
Number of subjects: 0
Study 6132613 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 6132613 — intervention group
Group type: COMPARATOR
Intervention: Diazemuls
Number of subjects: 0
Study 6132613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study 29618054 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 427
Study 29618054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 29618054 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal resection (STR)
Number of subjects: 427
Study 29618054 — intervention group
Group type: COMPARATOR
Intervention: Gross-total resection
Number of subjects: 427
Study 28945493 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23% acidulated phosphate fluoride (APF) gel with cold atmospheric plasma (CAP)
Number of subjects: 0
Study 28945493 — intervention group
Group type: COMPARATOR
Intervention: 1.23% acidulated phosphate fluoride (APF) gel
Number of subjects: 0
Study 27120271 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate (CH)
Number of subjects: 45
Study 27120271 — intervention group
Group type: EXPERIMENTAL
Intervention: 61% ethanol solution with 1% chlorhexidine gluconate (ES/CH)
Number of subjects: 45
Study 27120271 — intervention group
Group type: COMPARATOR
Intervention: 30% 1‐propanol and 45% 2‐propanol solution (MPS)
Number of subjects: 45
Study 27120271 — intervention group
Group type: COMPARATOR
Intervention: 70% 2‐propanol solution (IPS)
Number of subjects: 45
Study 25262168 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-arts based creative engagement intervention (CEI) facilitated by experienced artists, up to eight sessions (four group and four one-to-one)
Number of subjects: 80
Study 25262168 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 80
Study 22362097 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide coated bio-active stent (BAS)
Number of subjects: 425
Study 22362097 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 425
Study 20304589 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endovascular repair
Number of subjects: 728
Study 20304589 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound surveillance
Number of subjects: 728
Study 16925861 — intervention group
Group type: EXPERIMENTAL
Intervention: P supplement 250 mg
Number of subjects: 14
Study 16925861 — intervention group
Group type: EXPERIMENTAL
Intervention: P supplement 750 mg
Number of subjects: 14
Study 16925861 — intervention group
Group type: EXPERIMENTAL
Intervention: P supplement 1500 mg
Number of subjects: 14
Study 16925861 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg P)
Number of subjects: 14
Study 14624045 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated acenocoumarol dosages
Number of subjects: 15940
Study 14624045 — intervention group
Group type: COMPARATOR
Intervention: Traditionally fixed acenocoumarol dosages
Number of subjects: 15940
Study 10719952 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administration via target‐controlled infusion
Number of subjects: 270
Study 10719952 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administration in patients older than 60 years
Number of subjects: 270
Study 10719952 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administration in children
Number of subjects: 270
Study 10719952 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous data for propofol administration
Number of subjects: 270
Study 10719952 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus data for propofol administration
Number of subjects: 270
Study 9021354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential step‐up and step‐down protocol
Number of subjects: 56
Study 9021354 — intervention group
Group type: COMPARATOR
Intervention: Classic step‐up protocol
Number of subjects: 56
Study 1389840 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 140
Study 1389840 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 140
Study 1389840 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Propofol combination
Number of subjects: 140
Study 3931136 — intervention group
Group type: EXPERIMENTAL
Intervention: methylclonazepam 1 mg
Number of subjects: 18
Study 3931136 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 2.5 mg
Number of subjects: 18
Study 3931136 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 31813635 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam accelerated partial breast irradiation (APBI) - 38.5 Gy in ten fractions delivered twice per day over 5-8 days
Number of subjects: 2135
Study 31813635 — intervention group
Group type: COMPARATOR
Intervention: Whole breast irradiation - 42.5 Gy in 16 fractions once per day over 21 days or 50 Gy in 25 fractions once per day over 35 days
Number of subjects: 2135
Study 26501196 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat application tourniquet (CAT) applied at mid-thigh level
Number of subjects: 145
Study 26501196 — intervention group
Group type: COMPARATOR
Intervention: Combat application tourniquet (CAT)
Number of subjects: 145
Study 26133135 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorganic bone mineral-collagen membranes (BB)
Number of subjects: 10
Study 26133135 — intervention group
Group type: COMPARATOR
Intervention: Betatricalcium phosphate-pericardium collagen membranes (CJ)
Number of subjects: 10
Study 23352095 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 20
Study 23352095 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stent (EES)
Number of subjects: 20
Study 20937506 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 360
Study 20937506 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 360
Study 19823969 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified release 100 mg lamotrigine tablet (formulations L-1, L-2, L-3)
Number of subjects: 12
Study 17110897 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIpii)
Number of subjects: 275
Study 15337326 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐20 mg) added to mood stabilizer therapy
Number of subjects: 336
Study 15337326 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to mood stabilizer therapy
Number of subjects: 336
Study 12230419 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended thromboprophylaxis with warfarin for 4 more weeks
Number of subjects: 360
Study 12230419 — intervention group
Group type: COMPARATOR
Intervention: Control group (stopped warfarin at hospital discharge)
Number of subjects: 360
Study 9686768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg three times a day for 8 weeks
Number of subjects: 0
Study 9686768 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 0
Study 9686768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone with oral selegiline (5 mg in the morning and midday) during the second 4 weeks
Number of subjects: 0
Study 9686768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 0
Study 9686768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8134810 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 0
Study 8134810 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 2527935 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 13
Study 2527935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1100359 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2PO3F toothpaste with regular tooth cleaning
Number of subjects: 0
Study 1100359 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with regular but insufficient tooth cleaning
Number of subjects: 0
Study 29722110 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 h haemodialysis
Number of subjects: 12
Study 29722110 — intervention group
Group type: COMPARATOR
Intervention: 4 h haemodiafiltration
Number of subjects: 12
Study 29722110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresenius FX80 dialyser
Number of subjects: 12
Study 29722110 — intervention group
Group type: COMPARATOR
Intervention: Nipro Elisio
Number of subjects: 12
Study 29231544 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint embedding (once a week for 8 weeks)
Number of subjects: 56
Study 29231544 — intervention group
Group type: COMPARATOR
Intervention: Oral lactulose (3 times a day for 8 weeks)
Number of subjects: 56
Study 29231544 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint embedding
Number of subjects: 56
Study 25956020 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWD)
Number of subjects: 338
Study 23294293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prion-filtered red cell concentrates (PF‐RCC)
Number of subjects: 590
Study 23294293 — intervention group
Group type: COMPARATOR
Intervention: Standard red cell concentrates (RCC)
Number of subjects: 590
Study 20850853 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUS harmonic scalpel (group A, n = 45)
Number of subjects: 90
Study 20850853 — intervention group
Group type: COMPARATOR
Intervention: HARMONIC ACE (group B, n = 45)
Number of subjects: 90
Study 17879256 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 40
Study 17879256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16570898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 60
Study 16570898 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 60
Study 14644865 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum human cartilage glycoprotein 39 (HC gp39)
Number of subjects: 121
Study 14644865 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 121
Study 14644865 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of affected joints (NAJ)
Number of subjects: 121
Study 11432215 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen only (650 mg)
Number of subjects: 14
Study 11432215 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen plus cooling blanket (18 degrees C)
Number of subjects: 14
Study 11432215 — intervention group
Group type: COMPARATOR
Intervention: Physical cooling only (cooling blanket at 18 degrees C)
Number of subjects: 14
Study 9209244 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/day during 6 days)
Number of subjects: 13
Study 9209244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8260476 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 0
Study 8260476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 0
Study 8260476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-beet fibre (SBF)
Number of subjects: 0
Study 8260476 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 0
Study 8260476 — intervention group
Group type: COMPARATOR
Intervention: NSP-free control meal
Number of subjects: 0
Study 8260476 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal containing cholestyramine
Number of subjects: 0
Study 2893564 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 20
Study 2893564 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.12 mg/kg
Number of subjects: 20
Study 31375226 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual presentation + leaflet
Number of subjects: 165
Study 31375226 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual presentation + generic mind map
Number of subjects: 165
Study 31375226 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual presentation + customized mind map
Number of subjects: 165
Study 31375226 — intervention group
Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 165
Study 31375226 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic mind map
Number of subjects: 165
Study 31375226 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized mind map
Number of subjects: 165
Study 31375226 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual presentation + written information methods
Number of subjects: 165
Study 31375226 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents
Number of subjects: 165
Study 31375226 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between patient and parent knowledge scores
Number of subjects: 165
Study 29056020 — intervention group
Group type: EXPERIMENTAL
Intervention: Three dimensional human body scanning system BurnCalc
Number of subjects: 48
Study 29056020 — intervention group
Group type: COMPARATOR
Intervention: NIH Image J method
Number of subjects: 48
Study 29056020 — intervention group
Group type: COMPARATOR
Intervention: Transparency tracing method
Number of subjects: 48
Study 24782108 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection femoral nerve block (FNB) with intravenous PCA opioid
Number of subjects: 200
Study 24782108 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FNB)
Number of subjects: 200
Study 24782108 — intervention group
Group type: COMPARATOR
Intervention: PCA opioid alone
Number of subjects: 200
Study 22374331 — intervention group
Group type: EXPERIMENTAL
Intervention: oral sorafenib 400 mg twice a day
Number of subjects: 602
Study 22374331 — intervention group
Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 602
Study 20850133 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant beverage rich in polyphenols
Number of subjects: 100
Study 20850133 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 100
Study 17669023 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP‐2/ACS (0.2 mg/mL)
Number of subjects: 27
Study 17669023 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP‐2/ACS (0.56 mg/mL)
Number of subjects: 27
Study 17669023 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP‐2/ACS (0.2 mg/mL) and rhBMP‐2/ACS (0.56 mg/mL)
Number of subjects: 27
Study 17669023 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 27
Study 15615875 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing, quadrant by quadrant, at two‐week intervals (NC)
Number of subjects: 71
Study 15615875 — intervention group
Group type: COMPARATOR
Intervention: Full‐mouth scaling and root planing within 24 hrs (FRP)
Number of subjects: 71
Study 15615875 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐mouth disinfection within 24 hrs, including antiseptics (CHX or F for 2 mos, or CHX for 2 mos followed by F for 6 mos (CHX+F))
Number of subjects: 71
Study 12464992 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-induced decrease in mean arterial pressure (MAP)
Number of subjects: 2640
Study 12464992 — intervention group
Group type: COMPARATOR
Intervention: Control of blood pressure
Number of subjects: 2640
Study 10657735 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol treatment (0.1 mg 17beta-estradiol daily via transdermal patches)
Number of subjects: 43
Study 10657735 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (placebo via transdermal patches)
Number of subjects: 43
Study 10657735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1.5 mg) and hCRH (100 microgram)
Number of subjects: 43
Study 10657735 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 43
Study 7596696 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 129
Study 7596696 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 129
Study 7596696 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful biofeedback treatment
Number of subjects: 129
Study 2173282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment (0.4 g/kg body weight every 2 weeks)
Number of subjects: 15
Study 2173282 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15
Study 2173282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patient groups (IVIG and placebo)
Number of subjects: 15
Study 2173282 — intervention group
Group type: COMPARATOR
Intervention: Seropositive controls
Number of subjects: 15
Study 7352955 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g vitamin C daily (Group II)
Number of subjects: 40
Study 7352955 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g vitamin C daily (Group III)
Number of subjects: 40
Study 7352955 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g vitamin C daily for the first 20 days (in a separate group of 40 patients with acute myocardial infarction)
Number of subjects: 40
Study 7352955 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group for acute myocardial infarction patients)
Number of subjects: 40
Study 31825692 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 0
Study 31825692 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab and ipilimumab combination therapy
Number of subjects: 0
Study 31150431 — intervention group
Group type: EXPERIMENTAL
Intervention: Early condition (participants presented with examples referring to memories from age 1-2)
Number of subjects: 619
Study 31150431 — intervention group
Group type: EXPERIMENTAL
Intervention: Late condition (participants presented with examples referring to memories from age 5-6)
Number of subjects: 619
Study 31150431 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants presented with examples that did not contain any age cues)
Number of subjects: 619
Study 31150431 — intervention group
Group type: EXPERIMENTAL
Intervention: Snapshot memories
Number of subjects: 619
Study 31150431 — intervention group
Group type: EXPERIMENTAL
Intervention: Event memories
Number of subjects: 619
Study 28086896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS)
Number of subjects: 35
Study 28086896 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (control)
Number of subjects: 35
Study 26604721 — intervention group
Group type: EXPERIMENTAL
Intervention: GCQID group (1,200 mg glucosamine hydrochloride, 60 mg chondroitin sulfate, 45 mg type II collagen peptides, 90 mg quercetin glycosides, 10 mg imidazole peptides, 5 μg vitamin D per day)
Number of subjects: 100
Study 26604721 — intervention group
Group type: EXPERIMENTAL
Intervention: GCQID group
Number of subjects: 100
Study 23355041 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of gemcitabine and S‐1 (gemcitabine 1,000 mg/m(2) on days 1 and 15 and S‐1 40 mg/m(2) b.i.d. on days 1‐14, repeated every 4 weeks)
Number of subjects: 62
Study 23355041 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (gemcitabine 1,000 mg/m(2) on days 1, 8, and 15, repeated every 4 weeks)
Number of subjects: 62
Study 23355041 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of gemcitabine and S‐1
Number of subjects: 62
Study 23355041 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine monotherapy
Number of subjects: 62
Study 21188597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal steroid (INS) therapy (mometasone furoate)
Number of subjects: 55
Study 21188597 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency turbinoplasty (RFT)
Number of subjects: 55
Study 19265046 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor Seven for Acute Hemorrhagic Stroke (FAST) intervention
Number of subjects: 657
Study 19265046 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 657